Persephone Biosciences vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics; founded 2017 in San Diego; received BARDA funding for microbiome-based diagnostics;
About
Persephone Biosciences is a biotechnology company founded in 2017 by Stephanie Culler and Chris Calvert and based in San Diego, California. The company focuses on decoding the human gut microbiome to develop diagnostics and therapeutics in oncology and neonatal health. Its core thesis is that the composition of a patient's microbiome significantly affects how they respond to cancer immunotherapies such as checkpoint inhibitors — a hypothesis supported by a growing body of peer-reviewed clinical research. Persephone's diagnostic platform aims to predict immunotherapy response from a patient's microbiome signature prior to treatment initiation.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Persephone Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.